Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride

Abstract To assess the predictive and prognostic aim of interim and end-treatment 18F-fluorocholine PET/CT (FCH-PET/CT) and 99mTc-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with Radium 223 dichloride (223R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana María García Vicente, Mariano Amo-Salas, Javier Cassinello Espinosa, Roberto Gómez Díaz, Ángel Soriano Castrejón
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/93526451f9f1450195f654660d1da40e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93526451f9f1450195f654660d1da40e
record_format	dspace
spelling	oai:doaj.org-article:93526451f9f1450195f654660d1da40e2021-12-02T14:23:32ZInterim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride10.1038/s41598-021-86759-12045-2322https://doaj.org/article/93526451f9f1450195f654660d1da40e2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86759-1https://doaj.org/toc/2045-2322Abstract To assess the predictive and prognostic aim of interim and end-treatment 18F-fluorocholine PET/CT (FCH-PET/CT) and 99mTc-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with Radium 223 dichloride (223Ra). Prospective and multicentre ChoPET-Rad study including 82 patients with CRPC-BM. Baseline, after 3 (interim) and 6 doses (end-treatment) BS and FCH PET/CT were performed in patients who meet the study criteria. Clinical variables, imaging and clinical progression were obtained and their association with progression free survival (PFS), and overall survival (OS) was studied. Agreement between BS and FCH PET/CT response was assessed using Kappa (K) analysis. Median of PFS and OS was 3 and 16 months, respectively. Agreement between interim BS and FCH PET/CT was weak (K: 0.28; p = 0.004). No agreement was observed between end-treatment diagnostic studies. Interim and end-treatment FCH PET/CT were related to PFS (p = 0.011 and p < 0.001, respectively). Therapeutic failure and interim BS and FCH PET/CT showed association with OS (p < 0.001, p = 0.037 and p = 0.008, respectively). Interim and end-treatment FCH PET/CT were good predictors of biochemical progression in patients treated with 223Ra. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.Ana María García VicenteMariano Amo-SalasJavier Cassinello EspinosaRoberto Gómez DíazÁngel Soriano CastrejónNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ana María García Vicente Mariano Amo-Salas Javier Cassinello Espinosa Roberto Gómez Díaz Ángel Soriano Castrejón Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
description	Abstract To assess the predictive and prognostic aim of interim and end-treatment 18F-fluorocholine PET/CT (FCH-PET/CT) and 99mTc-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with Radium 223 dichloride (223Ra). Prospective and multicentre ChoPET-Rad study including 82 patients with CRPC-BM. Baseline, after 3 (interim) and 6 doses (end-treatment) BS and FCH PET/CT were performed in patients who meet the study criteria. Clinical variables, imaging and clinical progression were obtained and their association with progression free survival (PFS), and overall survival (OS) was studied. Agreement between BS and FCH PET/CT response was assessed using Kappa (K) analysis. Median of PFS and OS was 3 and 16 months, respectively. Agreement between interim BS and FCH PET/CT was weak (K: 0.28; p = 0.004). No agreement was observed between end-treatment diagnostic studies. Interim and end-treatment FCH PET/CT were related to PFS (p = 0.011 and p < 0.001, respectively). Therapeutic failure and interim BS and FCH PET/CT showed association with OS (p < 0.001, p = 0.037 and p = 0.008, respectively). Interim and end-treatment FCH PET/CT were good predictors of biochemical progression in patients treated with 223Ra. Therapeutic failure and progression in interim BS or FCH PET/CT were adverse factors for OS.
format	article
author	Ana María García Vicente Mariano Amo-Salas Javier Cassinello Espinosa Roberto Gómez Díaz Ángel Soriano Castrejón
author_facet	Ana María García Vicente Mariano Amo-Salas Javier Cassinello Espinosa Roberto Gómez Díaz Ángel Soriano Castrejón
author_sort	Ana María García Vicente
title	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
title_short	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
title_full	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
title_fullStr	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
title_full_unstemmed	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
title_sort	interim and end-treatment 18f-fluorocholine pet/ct and bone scan in prostate cancer patients treated with radium 223 dichloride
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/93526451f9f1450195f654660d1da40e
work_keys_str_mv	AT anamariagarciavicente interimandendtreatment18ffluorocholinepetctandbonescaninprostatecancerpatientstreatedwithradium223dichloride AT marianoamosalas interimandendtreatment18ffluorocholinepetctandbonescaninprostatecancerpatientstreatedwithradium223dichloride AT javiercassinelloespinosa interimandendtreatment18ffluorocholinepetctandbonescaninprostatecancerpatientstreatedwithradium223dichloride AT robertogomezdiaz interimandendtreatment18ffluorocholinepetctandbonescaninprostatecancerpatientstreatedwithradium223dichloride AT angelsorianocastrejon interimandendtreatment18ffluorocholinepetctandbonescaninprostatecancerpatientstreatedwithradium223dichloride
_version_	1718391439750070272

Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride

Ejemplares similares